Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 491

1.

Pathophysiology and Treatment of Gastrointestinal Motility Disorders in the Acutely Ill.

Deane AM, Chapman MJ, Reintam Blaser A, McClave SA, Emmanuel A.

Nutr Clin Pract. 2018 Oct 7. doi: 10.1002/ncp.10199. [Epub ahead of print] Review.

PMID:
30294835
2.

A Case Study of Genomic Instability in an Industrial Strain of Saccharomyces cerevisiae.

Rodrigues-Prause A, Sampaio NMV, Gurol TM, Aguirre GM, Sedam HNC, Chapman MJ, Malc EP, Ajith VP, Chakraborty P, Tizei PA, Pereira GAG, Mieczkowski PA, Nishant KT, Argueso JL.

G3 (Bethesda). 2018 Sep 25. pii: g3.200446.2018. doi: 10.1534/g3.118.200446. [Epub ahead of print]

3.

A Quality Control Study of the Adherence to Recommended Physiological Targets for the Management of Brain-Dead Organ Donors in South Australian Intensive Care Units.

Sampson BG, Wilson SR, Finnis ME, Hodak AM, Jones PN, O'Connor SL, Chapman MJ.

Prog Transplant. 2018 Sep 16:1526924818800053. doi: 10.1177/1526924818800053. [Epub ahead of print]

PMID:
30222049
4.

Cholesterol efflux capacity of large, small and total HDL particles is unaltered by atorvastatin in patients with type 2 diabetes.

Muñoz-Hernandez L, Ortiz-Bautista RJ, Brito-Córdova G, Lozano-Arvizu F, Saucedo S, Pérez-Méndez O, Zentella-Dehesa A, Dauteuille C, Lhomme M, Lesnik P, Chapman MJ, Kontush A, Aguilar Salinas CA.

Atherosclerosis. 2018 Oct;277:72-79. doi: 10.1016/j.atherosclerosis.2018.08.027. Epub 2018 Aug 24.

PMID:
30176567
5.

Lipoprotein-apheresis in familial hypercholesterolemia: Long-term patient compliance in a French cohort.

Beliard S, Gallo A, Duchêne E, Carrié A, Bittar R, Chapman MJ, Bruckert E, Saheb S.

Atherosclerosis. 2018 Oct;277:66-71. doi: 10.1016/j.atherosclerosis.2018.08.007. Epub 2018 Aug 18.

PMID:
30176566
6.

Why is hypercholesterolaemia so prevalent? A view from evolutionary medicine.

Laufs U, Dent R, Kostenuik PJ, Toth PP, Catapano AL, Chapman MJ.

Eur Heart J. 2018 Aug 28. doi: 10.1093/eurheartj/ehy479. [Epub ahead of print] No abstract available.

PMID:
30169643
7.

Is 45 years-of-age the cut-off for using autologous oocytes?

Yovich JL, Chapman MJ, Keane KN, Savulescu J.

Reprod Biomed Online. 2018 Aug;37(2):123-125. doi: 10.1016/j.rbmo.2018.06.016. No abstract available.

PMID:
30075838
8.

Nutrition Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double-Blind, Placebo-Controlled Trial of the Motilin Receptor Agonist Camicinal (GSK962040): The NUTRIATE Study.

Deane AM, Lamontagne F, Dukes GE, Neil D, Vasist L, Barton ME, Hacquoil K, Ou X, Richards D, Stelfox HT, Mehta S, Day AG, Chapman MJ, Heyland DK.

JPEN J Parenter Enteral Nutr. 2018 Jul;42(5):949-959. doi: 10.1002/jpen.1038. Epub 2017 Dec 28.

PMID:
29957868
9.

Observed appetite and nutrient intake three months after ICU discharge.

Chapple LS, Weinel LM, Abdelhamid YA, Summers MJ, Nguyen T, Kar P, Lange K, Chapman MJ, Deane AM.

Clin Nutr. 2018 May 9. pii: S0261-5614(18)30174-2. doi: 10.1016/j.clnu.2018.05.002. [Epub ahead of print]

PMID:
29778511
10.

Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM.

Langlois MR, Chapman MJ, Cobbaert C, Mora S, Remaley AT, Ros E, Watts GF, Borén J, Baum H, Bruckert E, Catapano A, Descamps OS, von Eckardstein A, Kamstrup PR, Kolovou G, Kronenberg F, Langsted A, Pulkki K, Rifai N, Sypniewska G, Wiklund O, Nordestgaard BG; European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative.

Clin Chem. 2018 Jul;64(7):1006-1033. doi: 10.1373/clinchem.2018.287037. Epub 2018 May 14.

PMID:
29760220
11.

Niacin action in the atherogenic mixed dyslipidemia of metabolic syndrome: Insights from metabolic biomarker profiling and network analysis.

Adiels M, Chapman MJ, Robillard P, Krempf M, Laville M, Borén J; Niacin Study Group.

J Clin Lipidol. 2018 May - Jun;12(3):810-821.e1. doi: 10.1016/j.jacl.2018.03.083. Epub 2018 Mar 29.

12.

Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract.

Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, De Backer G, Hegele RA, Hovingh GK, Jacobson TA, Krauss RM, Laufs U, Leiter LA, März W, Nordestgaard BG, Raal FJ, Roden M, Santos RD, Stein EA, Stroes ES, Thompson PD, Tokgözoglu L, Vladutiu GD, Gencer B, Stock JK, Ginsberg HN, Chapman MJ; European Atherosclerosis Society Consensus Panel.

Eur Heart J. 2018 Jul 14;39(27):2526-2539. doi: 10.1093/eurheartj/ehy182.

13.

Impact of Lipoproteins on Atherobiology: Emerging Insights.

Feng M, Rached F, Kontush A, Chapman MJ.

Cardiol Clin. 2018 May;36(2):193-201. doi: 10.1016/j.ccl.2017.10.001. Review.

PMID:
29609748
14.

New prospects for PCSK9 inhibition?

Landmesser U, Chapman MJ, Stock JK, Amarenco P, Belch JJF, Borén J, Farnier M, Ference BA, Gielen S, Graham I, Grobbee DE, Hovingh GK, Lüscher TF, Piepoli MF, Ray KK, Stroes ES, Wiklund O, Windecker S, Zamorano JL, Pinto F, Tokgözoglu L, Bax JJ, Catapano AL; European Society of Cardiology/European Atherosclerosis Society Task Force.

Eur Heart J. 2018 Jul 14;39(27):2600-2601. doi: 10.1093/eurheartj/ehy147. No abstract available.

PMID:
29579192
15.

Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP.

Chapman MJ, Orsoni A, Robillard P, Therond P, Giral P.

J Clin Lipidol. 2018 May - Jun;12(3):784-800.e4. doi: 10.1016/j.jacl.2018.02.001. Epub 2018 Feb 9.

16.

The disconnect between nutrition guidelines and evidence: how much protein should I prescribe to this critically ill patient?

Deane AM, Peake SL, Chapman MJ.

Crit Care Resusc. 2018 Mar;20(1):3-5. No abstract available.

PMID:
29458315
17.

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.

Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Monique Verschuren WM, Vlachopoulos C, Wood DA, Luis Zamorano J; Additional Contributor, Cooney MT.

Rev Esp Cardiol (Engl Ed). 2017 Feb;70(2):115. doi: 10.1016/j.rec.2017.01.002. English, Spanish. No abstract available.

PMID:
29389351
18.

No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data.

Harvey PD, Sabbagh MN, Harrison JE, Ginsberg HN, Chapman MJ, Manvelian G, Moryusef A, Mandel J, Farnier M.

Eur Heart J. 2018 Feb 1;39(5):374-381. doi: 10.1093/eurheartj/ehx661.

19.

Small dense HDLs display potent vasorelaxing activity, reflecting their elevated content of sphingosine-1-phosphate.

Perségol L, Darabi M, Dauteuille C, Lhomme M, Chantepie S, Rye KA, Therond P, Chapman MJ, Salvayre R, Nègre-Salvayre A, Lesnik P, Monier S, Kontush A.

J Lipid Res. 2018 Jan;59(1):25-34. doi: 10.1194/jlr.M076927. Epub 2017 Nov 17.

PMID:
29150495
20.

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.

Landmesser U, Chapman MJ, Stock JK, Amarenco P, Belch JJF, Borén J, Farnier M, Ference BA, Gielen S, Graham I, Grobbee DE, Hovingh GK, Lüscher TF, Piepoli MF, Ray KK, Stroes ES, Wiklund O, Windecker S, Zamorano JL, Pinto F, Tokgözoglu L, Bax JJ, Catapano AL.

Eur Heart J. 2018 Apr 7;39(14):1131-1143. doi: 10.1093/eurheartj/ehx549. No abstract available.

PMID:
29045644
21.

A scoping review of use of wearable devices to evaluate outcomes in survivors of critical illness.

Gluck S, Chapple LS, Chapman MJ, Iwashyna TJ, Deane AM.

Crit Care Resusc. 2017 Sep;19(3):197-204. Review.

PMID:
28866969
22.

Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.

Ference BA, Kastelein JJP, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK, Packard CJ, Laufs U, Brook RD, Oliver-Williams C, Butterworth AS, Danesh J, Smith GD, Catapano AL, Sabatine MS.

JAMA. 2017 Sep 12;318(10):947-956. doi: 10.1001/jama.2017.11467.

23.

Paradoxical coronary artery disease in humans with hyperalphalipoproteinemia is associated with distinct differences in the high-density lipoprotein phosphosphingolipidome.

Hancock-Cerutti W, Lhomme M, Dauteuille C, Lecocq S, Chapman MJ, Rader DJ, Kontush A, Cuchel M.

J Clin Lipidol. 2017 Sep - Oct;11(5):1192-1200.e3. doi: 10.1016/j.jacl.2017.06.018. Epub 2017 Jul 8.

PMID:
28826666
24.

HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology.

Rosenson RS, Brewer HB Jr, Barter PJ, Björkegren JLM, Chapman MJ, Gaudet D, Kim DS, Niesor E, Rye KA, Sacks FM, Tardif JC, Hegele RA.

Nat Rev Cardiol. 2018 Jan;15(1):9-19. doi: 10.1038/nrcardio.2017.115. Epub 2017 Aug 10. Review.

PMID:
28795686
25.

Therapeutic targeting of HMGB1 during experimental sepsis modulates the inflammatory cytokine profile to one associated with improved clinical outcomes.

Stevens NE, Chapman MJ, Fraser CK, Kuchel TR, Hayball JD, Diener KR.

Sci Rep. 2017 Jul 19;7(1):5850. doi: 10.1038/s41598-017-06205-z.

26.

The rapid and accurate categorisation of critically ill patients (RACE) to identify outcomes of interest for longitudinal studies: a feasibility study.

Deane AM, Hodgson CL, Young P, Little L, Singh V, Poole A, Young M, Mackle D, Lange K, Williams P, Peake SL, Chapman MJ, Iwashyna TJ.

Anaesth Intensive Care. 2017 Jul;45(4):476-484.

27.

Protein delivery and clinical outcomes in the critically ill: a systematic review and meta-analysis.

Davies ML, Chapple LS, Chapman MJ, Moran JL, Peake SL.

Crit Care Resusc. 2017 Jun;19(2):117-127. Review.

PMID:
28651507
28.

Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN.

Puri R, Ballantyne CM, Hoogeveen RC, Shao M, Barter P, Libby P, Chapman MJ, Erbel R, Arsenault BJ, Raichlen JS, Nissen SE, Nicholls SJ.

Atherosclerosis. 2017 Aug;263:137-144. doi: 10.1016/j.atherosclerosis.2017.06.026. Epub 2017 Jun 15.

PMID:
28641153
29.

Structure-function relationships in reconstituted HDL: Focus on antioxidative activity and cholesterol efflux capacity.

Cukier AMO, Therond P, Didichenko SA, Guillas I, Chapman MJ, Wright SD, Kontush A.

Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Sep;1862(9):890-900. doi: 10.1016/j.bbalip.2017.05.010. Epub 2017 May 18.

PMID:
28529180
30.

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.

Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgözoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL.

Eur Heart J. 2017 Aug 21;38(32):2459-2472. doi: 10.1093/eurheartj/ehx144. Review.

31.

Exogenous glucagon-like peptide-1 attenuates glucose absorption and reduces blood glucose concentration after small intestinal glucose delivery in critical illness.

Miller A, Deane AM, Plummer MP, Cousins CE, Chapple LS, Horowitz M, Chapman MJ.

Crit Care Resusc. 2017 Mar;19(1):37-42.

PMID:
28215130
32.

Longitudinal changes in anthropometrics and impact on self-reported physical function after traumatic brain injury.

Chapple LS, Deane AM, Williams LT, Strickland R, Schultz C, Lange K, Heyland DK, Chapman MJ.

Crit Care Resusc. 2017 Mar;19(1):29-36.

PMID:
28215129
33.

Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial.

Marty FM, Vidal-Puigserver J, Clark C, Gupta SK, Merino E, Garot D, Chapman MJ, Jacobs F, Rodriguez-Noriega E, Husa P, Shortino D, Watson HA, Yates PJ, Peppercorn AF.

Lancet Respir Med. 2017 Feb;5(2):135-146. doi: 10.1016/S2213-2600(16)30435-0. Epub 2017 Jan 14.

PMID:
28094141
34.

Occult upper gastrointestinal mucosal abnormalities in critically ill patients.

Ovenden C, Plummer MP, Selvanderan S, Donaldson TA, Nguyen NQ, Weinel LM, Finnis ME, Summers MJ, Ali Abdelhamid Y, Chapman MJ, Rayner CK, Deane AM.

Acta Anaesthesiol Scand. 2017 Feb;61(2):216-223. doi: 10.1111/aas.12844. Epub 2016 Dec 13.

PMID:
27966213
35.

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.

Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, Voros S, Giugliano RP, Davey Smith G, Fazio S, Sabatine MS.

N Engl J Med. 2016 Dec 1;375(22):2144-2153.

36.

[2016 ESC/EAS Guidelines for the Management of Dyslipidaemias].

Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL.

Kardiol Pol. 2016;74(11):1234-1318. doi: 10.5603/KP.2016.0157. Polish. No abstract available.

37.

Poor glycemic control in type 2 diabetes enhances functional and compositional alterations of small, dense HDL3c.

Gomez Rosso L, Lhomme M, Meroño T, Dellepiane A, Sorroche P, Hedjazi L, Zakiev E, Sukhorukov V, Orekhov A, Gasparri J, Chapman MJ, Brites F, Kontush A.

Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Feb;1862(2):188-195. doi: 10.1016/j.bbalip.2016.10.014. Epub 2016 Nov 2.

PMID:
27815221
38.

Statin action enriches HDL3 in polyunsaturated phospholipids and plasmalogens and reduces LDL-derived phospholipid hydroperoxides in atherogenic mixed dyslipidemia.

Orsoni A, Thérond P, Tan R, Giral P, Robillard P, Kontush A, Meikle PJ, Chapman MJ.

J Lipid Res. 2016 Nov;57(11):2073-2087. Epub 2016 Aug 31.

39.

European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk.

Landmesser U, Chapman MJ, Farnier M, Gencer B, Gielen S, Hovingh GK, Lüscher TF, Sinning D, Tokgözoglu L, Wiklund O, Zamorano JL, Pinto FJ, Catapano AL; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS).

Eur Heart J. 2017 Aug 1;38(29):2245-2255. doi: 10.1093/eurheartj/ehw480. No abstract available. Erratum in: Eur Heart J. 2017 Jan 21;:.

PMID:
27789571
40.

Weekend days are not required to accurately measure oral intake in hospitalised patients.

Chapple LS, Deane AM, Lange K, Kranz AJ, Williams LT, Chapman MJ.

J Hum Nutr Diet. 2017 Jun;30(3):378-384. doi: 10.1111/jhn.12432. Epub 2016 Oct 6.

PMID:
27709690
41.

Lifestyle intervention enhances high-density lipoprotein function among patients with metabolic syndrome only at normal low-density lipoprotein cholesterol plasma levels.

Hansel B, Bonnefont-Rousselot D, Orsoni A, Bittar R, Giral P, Roussel R, Marre M, Mohammedi K, Bruckert E, Chapman MJ, Kontush A.

J Clin Lipidol. 2016 Sep-Oct;10(5):1172-81. doi: 10.1016/j.jacl.2016.05.008. Epub 2016 May 14.

PMID:
27678434
42.

Pantoprazole or Placebo for Stress Ulcer Prophylaxis (POP-UP): Randomized Double-Blind Exploratory Study.

Selvanderan SP, Summers MJ, Finnis ME, Plummer MP, Ali Abdelhamid Y, Anderson MB, Chapman MJ, Rayner CK, Deane AM.

Crit Care Med. 2016 Oct;44(10):1842-50. doi: 10.1097/CCM.0000000000001819.

PMID:
27635481
43.

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).

Authors/Task Force Members:, Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL.

Atherosclerosis. 2016 Oct;253:281-344. doi: 10.1016/j.atherosclerosis.2016.08.018. Epub 2016 Sep 1. No abstract available.

PMID:
27594540
44.

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.

Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT; ESC Scientific Document Group.

Eur Heart J. 2016 Oct 14;37(39):2999-3058. doi: 10.1093/eurheartj/ehw272. Epub 2016 Aug 27. No abstract available.

45.

A low-fidelity, high-functionality, inexpensive ultrasound-guided nerve block model.

Micheller D, Chapman MJ, Cover M, Porath JD, Theyyunni N, Kessler R, Huang R.

CJEM. 2017 Jan;19(1):58-60. doi: 10.1017/cem.2016.335. Epub 2016 Aug 1. No abstract available.

PMID:
27478036
46.

The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial.

Chapman MJ, Deane AM, O'Connor SL, Nguyen NQ, Fraser RJ, Richards DB, Hacquoil KE, Vasist Johnson LS, Barton ME, Dukes GE.

Crit Care. 2016 Aug 1;20(1):232. doi: 10.1186/s13054-016-1420-4.

47.

Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity.

Didichenko SA, Navdaev AV, Cukier AM, Gille A, Schuetz P, Spycher MO, Thérond P, Chapman MJ, Kontush A, Wright SD.

Circ Res. 2016 Sep 2;119(6):751-63. doi: 10.1161/CIRCRESAHA.116.308685. Epub 2016 Jul 19.

48.

Liberal Glycemic Control in Critically Ill Patients With Type 2 Diabetes: An Exploratory Study.

Kar P, Plummer MP, Bellomo R, Jenkins AJ, Januszewski AS, Chapman MJ, Jones KL, Horowitz M, Deane AM.

Crit Care Med. 2016 Sep;44(9):1695-703. doi: 10.1097/CCM.0000000000001815.

PMID:
27315191
49.

The effect of augmenting early nutritional energy delivery on quality of life and employment status one year after ICU admission.

Reid DB, Chapple LS, O'Connor SN, Bellomo R, Buhr H, Chapman MJ, Davies AR, Eastwood GM, Ferrie S, Lange K, McIntyre J, Needham DM, Peake SL, Rai S, Ridley EJ, Rodgers H, Deane AM.

Anaesth Intensive Care. 2016 May;44(3):406-12.

50.

Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel.

Santos RD, Gidding SS, Hegele RA, Cuchel MA, Barter PJ, Watts GF, Baum SJ, Catapano AL, Chapman MJ, Defesche JC, Folco E, Freiberger T, Genest J, Hovingh GK, Harada-Shiba M, Humphries SE, Jackson AS, Mata P, Moriarty PM, Raal FJ, Al-Rasadi K, Ray KK, Reiner Z, Sijbrands EJ, Yamashita S; International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel.

Lancet Diabetes Endocrinol. 2016 Oct;4(10):850-61. doi: 10.1016/S2213-8587(16)30041-9. Epub 2016 May 27. Review.

Supplemental Content

Loading ...
Support Center